负荷型慢性心衰 z-bo 2020-11-13 335

　　Objective: To study the effect and mechanism of liraglutide on heart function in rats with pressure overload chronic heart failure.

　　Method: 30 SD rats were randomly divided into sham operation group, heart failure group, and liraglutide group, with 10 rats in each group. In the heart failure group and liraglutide group, the abdominal aorta coarctation method was used to prepare models, and the sham operation group only threaded but not constricted. The liraglutide group was given subcutaneous injection of liraglutide at 2 mg/kg·d for 30 days after 12 weeks. The sham operation group and the heart failure group were given the same dose of normal saline. After 30 days of administration, the rats were weighed, and the pressure-volume system was used to detect hemodynamic indicators. At the same time, the various organs of the rats were weighed. After the rats were anesthetized, blood was drawn from the abdominal aorta and centrifuged to obtain serum, and the superoxide dismutase (SOD), B-type natriuretic peptide (BNP), and malondialdehyde (MDA) were determined according to the kit method.

　　Result: Heart weighing showed that the heart weight of the liraglutide group was significantly lower than that of the heart failure group (P<0.05). The hemodynamics measured by the pressure volume system showed that compared with the sham operation group, the values of Ves, Ved, Pmax, Pes, and Ped of rats in the liraglutide group were significantly reduced (P<0.05), dP/dt max, -dP/dt min, EF and PowMax values increased significantly (P<0.05). Compared with the heart failure group, the SOD value in the serum of rats in the liraglutide group was significantly increased (P<0.05), while the BNP value was significantly reduced (P<0.05).

　　Conclusion: Liraglutide can improve the systolic and diastolic function of the left ventricle in rats with heart failure, and reduce the damage of cardiomyocytes. The mechanism may be related to the antioxidant effect.